Aplastic anaemia is a rare but serious blood disorder that occurs when the bone marrow stops making enough new blood cells. When left without proper care, this condition can become life-threatening. However, modern medicine offers several treatment approaches, from supportive therapies to advanced stem cell transplantation, and researchers continue to explore new ways to help patients live longer and better lives.

Fighting back: how treatment helps restore blood cell production

The main goal of treating aplastic anaemia is to restore the bone marrow’s ability to produce healthy blood cells. When the bone marrow fails, the body runs short on red blood cells that carry oxygen, white blood cells that fight infection, and platelets that help stop bleeding. Treatment aims to address these deficiencies, reduce dangerous complications like severe infections and uncontrolled bleeding, and ultimately improve the patient’s quality of life. For some patients, treatment can even cure the condition completely.^[1][2]

The treatment approach depends on several factors. Doctors consider how severe the anaemia is, how quickly it developed, the patient’s age and overall health, and whether there is a suitable bone marrow donor available. Severe aplastic anaemia, where blood cell counts drop to extremely low levels, is a medical emergency that requires immediate hospitalization. In these cases, patients face serious risks and need urgent intervention to prevent life-threatening complications.^[8][9]

Medical societies and expert groups, such as the British Society for Haematology, have developed detailed guidelines to help doctors choose the most appropriate treatment for each patient. These guidelines are based on years of research and clinical experience. They recommend different strategies depending on whether the patient is young or older, whether the disease is mild or severe, and whether other health problems are present.^[11]

Standard treatments: the established path to managing aplastic anaemia

Blood transfusions: replacing what the body cannot make

Blood transfusions are one of the most common and immediate treatments for aplastic anaemia. Although they do not cure the disease or fix the bone marrow problem, they provide the blood cells that the body desperately needs. When a patient receives a transfusion, they are given blood components donated by healthy individuals, processed and tested to ensure safety.^[8][10]

There are two main types of transfusions used in aplastic anaemia. Red blood cell transfusions help raise the number of red blood cells in circulation. This relieves symptoms like extreme tiredness, weakness, and shortness of breath that come from not having enough oxygen-carrying cells. Patients often feel noticeably better after receiving red blood cells, though the effect is temporary because the transfused cells eventually wear out and need to be replaced.^[8]

Platelet transfusions are given to prevent or control bleeding. When platelet counts drop too low, even minor injuries can lead to serious bleeding problems. Patients may develop nosebleeds, bleeding gums, or bruises that appear without any obvious injury. In severe cases, internal bleeding can occur. Platelet transfusions help reduce these risks, though they need to be repeated regularly because platelets only survive for about a week in the bloodstream.^[8]

While transfusions are lifesaving, they do carry some risks. Repeated transfusions over time can lead to a buildup of iron in the body, a condition that can damage organs like the heart and liver. Doctors may prescribe medicines called iron chelators to remove excess iron. There is also a small risk of allergic reactions or infections from transfused blood, although modern screening makes this very rare.^[10]

Immunosuppressive therapy: calming the immune attack

Many cases of aplastic anaemia occur because the body’s immune system mistakenly attacks and destroys the stem cells in the bone marrow. To address this, doctors use medications that suppress or calm down the immune system, allowing the bone marrow to recover and start producing blood cells again. This approach is called immunosuppressive therapy, and it has become a cornerstone of treatment, especially for patients who cannot undergo stem cell transplantation.^[3][8]

The most commonly used immunosuppressive drug is anti-thymocyte globulin, often called ATG. This medicine is made from antibodies that target and destroy certain white blood cells responsible for attacking the bone marrow. ATG is typically given through a vein over several days in the hospital. Patients are monitored closely during treatment because ATG can cause side effects like fever, chills, and allergic reactions. Despite these challenges, ATG has proven very effective at helping many patients recover bone marrow function.^[10][11]

ATG is almost always combined with another drug called ciclosporin (also spelled cyclosporine). Ciclosporin works differently from ATG; it blocks certain signals that trigger the immune system to attack the bone marrow. This drug is taken by mouth, usually for several months or even years. The combination of ATG and ciclosporin, sometimes called triple immunosuppressive therapy when additional medications are added, has significantly improved survival rates, with more than 80% of patients seeing benefit.^[3][8]

Immunosuppressive therapy does have drawbacks. Because these drugs weaken the immune system, patients become more vulnerable to infections. They may need to take antibiotics or antifungal medicines to prevent infections while their immune system is suppressed. Some patients experience side effects like high blood pressure, kidney problems, or tremors from ciclosporin. Additionally, immunosuppressive therapy does not work for everyone, and some patients may see their blood counts improve only to drop again later, a situation called relapse.^[8][11]

Alemtuzumab: a newer immunosuppressive option

Alemtuzumab is a type of medicine called a monoclonal antibody. These are specially engineered proteins designed to seek out and attach to specific cells in the body. Alemtuzumab targets and destroys lymphocytes, a type of white blood cell that can attack bone marrow stem cells in aplastic anaemia. While alemtuzumab is not yet a standard first-choice treatment, it is being studied in clinical trials and has shown promise in treating certain types of aplastic anaemia where the immune system plays a strong role.^[10]

Alemtuzumab is already approved for treating some types of leukemia, and doctors have found it helpful for other conditions requiring immunosuppression. In aplastic anaemia, it offers another option for patients who do not respond to standard immunosuppressive therapy or who need additional treatment.^[10]

Androgens: hormones that stimulate blood cell production

Androgens are natural male hormones that can encourage the bone marrow to produce more red blood cells. In aplastic anaemia, doctors sometimes prescribe androgens to help improve anemia, particularly in patients with milder disease or those who have not responded well to other treatments. While androgens can be helpful, they are not effective for everyone, and they come with side effects such as masculinization (development of male characteristics), liver problems, and mood changes. For these reasons, androgens are used selectively and are not considered a primary treatment.^[10]

Stem cell transplantation: the only cure

Stem cell transplantation, also known as bone marrow transplantation, is currently the only treatment that can completely cure aplastic anaemia. In this procedure, the patient’s damaged bone marrow is replaced with healthy stem cells from a donor. These donor stem cells can grow and develop into all the different types of blood cells the body needs, effectively restoring normal bone marrow function.^[1][2]

Stem cell transplantation is most commonly recommended for younger patients, typically those under 30 or 40 years old, who have severe aplastic anaemia and a suitable donor. The best outcomes occur when the donor is a sibling with matching tissue types, but transplants can also be performed using donors from registries who are not related to the patient. Before the transplant, patients receive high doses of chemotherapy and sometimes radiation to destroy any remaining abnormal bone marrow cells and prevent the immune system from rejecting the donor cells.^[8][11]

While stem cell transplantation offers the possibility of a cure, it is a complex and risky procedure. Patients may experience serious complications, including infections, because the immune system is severely weakened during the process. Another major concern is graft-versus-host disease, a condition where the donor immune cells attack the patient’s body tissues. This can cause damage to the skin, liver, intestines, and other organs. Despite these risks, advances in transplant techniques and supportive care have greatly improved success rates, and many patients go on to live normal, healthy lives after transplantation.^[8]

Antibiotics and antifungals: preventing infections

Patients with aplastic anaemia have very low numbers of neutrophils, the white blood cells that fight infections. This condition, called neutropenia, makes patients highly vulnerable to bacterial and fungal infections that can quickly become life-threatening. To prevent infections, doctors often prescribe antibiotics and antifungal medications even before any signs of infection appear. This preventive approach is especially important during the early stages of treatment when blood cell counts are at their lowest.^[10]

If a patient develops a fever or shows signs of infection, they need immediate medical attention. Doctors typically start broad-spectrum antibiotics right away without waiting for test results, because delays can be dangerous when the immune system is so weak.^[10]

Treatment in clinical trials: exploring new frontiers

While standard treatments have improved outcomes for many patients with aplastic anaemia, they do not work for everyone. Some patients do not respond to immunosuppressive therapy, others experience relapses, and stem cell transplantation may not be an option due to lack of a suitable donor or patient age and health. This has driven researchers to investigate new and innovative treatments through clinical trials.^[3]

Clinical trials are carefully designed research studies that test new drugs, treatment combinations, or procedures to see if they are safe and effective. Trials are conducted in phases. Phase I trials focus primarily on safety, determining the right dose and watching for side effects in a small group of volunteers. Phase II trials expand the study to more participants and evaluate whether the treatment shows signs of working against the disease. Phase III trials compare the new treatment to the current standard treatment in large groups of patients to see if the new approach is better, as good, or worse.^[3]

Eltrombopag: stimulating platelet production and more

One of the most exciting developments in aplastic anaemia treatment is the use of eltrombopag, a drug originally developed to help the body make more platelets. Eltrombopag works by activating a receptor on bone marrow cells called the thrombopoietin receptor. When this receptor is stimulated, it encourages the bone marrow to produce not only platelets but also other types of blood cells.^[10]

Clinical trials have shown that eltrombopag can be particularly helpful for patients who have not responded to standard immunosuppressive therapy. Some studies have combined eltrombopag with ATG and ciclosporin as a first-line treatment, with promising results. Patients receiving this combination have shown improved blood counts and better overall responses compared to those receiving immunosuppressive therapy alone. Eltrombopag is taken by mouth, which makes it more convenient than intravenous treatments.^[10]

While eltrombopag has shown great promise, it is not without risks. Some patients develop elevated liver enzymes, which require monitoring through regular blood tests. There is also a concern that long-term use might increase the risk of developing other bone marrow disorders, such as myelodysplastic syndrome, although this is still being studied. Despite these concerns, eltrombopag represents an important advance in treatment options for aplastic anaemia.^[10]

New immunosuppressive strategies

Researchers continue to explore ways to make immunosuppressive therapy more effective and better tolerated. Some clinical trials are testing different doses or schedules of ATG and ciclosporin to see if outcomes can be improved. Others are investigating whether adding newer immunosuppressive drugs to the standard regimen can help more patients respond to treatment or reduce the risk of relapse.^[11]

One area of particular interest is understanding why some patients respond well to immunosuppressive therapy while others do not. By identifying specific characteristics of the immune system or genetic markers in patients, researchers hope to develop personalized treatment approaches that are tailored to each individual’s disease.^[11]

Alternative donor transplants: expanding access to cure

For many years, stem cell transplantation was only an option for patients who had a matched sibling donor. However, advances in transplant technology have made it possible to use donors who are not perfectly matched or who are not related to the patient. Clinical trials are exploring the use of haploidentical transplants, where the donor is a half-match, such as a parent or child, and unrelated donor transplants from volunteer registries.^[8][11]

These alternative donor transplants use special techniques to reduce the risk of graft-versus-host disease and transplant rejection. Early results have been encouraging, with many patients achieving successful engraftment and long-term survival. This is particularly important because it opens the possibility of cure to patients who previously had no suitable donor.^[11]

Understanding the mechanisms: research into disease causes

Clinical trials are not just about testing new drugs; they also help researchers understand why aplastic anaemia develops in the first place. Studies are investigating the role of specific autoantibodies (immune proteins that attack the body’s own cells) and changes in the bone marrow environment that contribute to stem cell failure. By understanding these underlying mechanisms, scientists hope to develop treatments that target the root causes of the disease rather than just managing symptoms.^[3]

Participating in clinical trials

Clinical trials for aplastic anaemia are conducted in specialized medical centers around the world, including in the United States, Europe, and other regions. Patients interested in participating in a trial should talk to their hematologist, who can help determine if they are eligible for any ongoing studies. Eligibility often depends on factors like the severity of the disease, previous treatments received, age, and overall health. Participating in a clinical trial gives patients access to cutting-edge treatments that are not yet widely available, and it also contributes to the advancement of medical knowledge that will help future patients.^[11]

Most common treatment methods

• Blood transfusions
  • Red blood cell transfusions to relieve anemia and fatigue
  • Platelet transfusions to prevent or control bleeding
  • Temporary relief of symptoms by replacing blood cells the bone marrow cannot produce
• Immunosuppressive therapy
  • Anti-thymocyte globulin (ATG) given intravenously to destroy immune cells attacking bone marrow
  • Ciclosporin taken orally to suppress immune system signals
  • Combination therapy with ATG and ciclosporin achieving survival rates exceeding 80%
  • Alemtuzumab, a monoclonal antibody being tested in clinical trials for certain types of aplastic anaemia
• Stem cell transplantation
  • Replacement of damaged bone marrow with healthy donor stem cells
  • The only treatment that can completely cure aplastic anaemia
  • Most suitable for younger patients with severe disease and matched donors
  • Alternative donor transplants expanding access to cure
• Medicines to stimulate blood cell production
  • Eltrombopag to activate thrombopoietin receptor and encourage bone marrow to produce blood cells
  • Androgens to stimulate red blood cell production in selected patients
• Infection prevention
  • Antibiotics to prevent bacterial infections during neutropenia
  • Antifungal medications to reduce risk of fungal infections
  • Immediate treatment with broad-spectrum antibiotics when fever or infection signs appear

Living with aplastic anaemia: practical guidance for patients and families

Managing aplastic anaemia is not just about medical treatments. Day-to-day life requires careful attention to prevent complications, especially when blood cell counts are low. Patients and their families need to take specific precautions to reduce the risk of infections, bleeding, and fatigue-related problems.^[13][14]

Preventing infections

Because patients with aplastic anaemia have weakened immune systems, avoiding infections is critical. Simple measures can make a big difference. Frequent handwashing is one of the most effective ways to prevent the spread of germs. Patients should wash their hands thoroughly with soap and water before eating, after using the bathroom, and after touching surfaces in public places. Family members should also practice good hand hygiene.^[14][15]

Staying away from crowded places, especially during cold and flu season, helps reduce exposure to infectious diseases. Patients should avoid close contact with people who are sick, even if it’s just a common cold. Family members who are ill should keep their distance until they are no longer contagious. Getting a flu vaccine every year is important, and patients should ask their doctor about other recommended vaccines.^[14][15]

Good dental hygiene is essential because infections in the mouth can spread to the bloodstream. Patients should brush their teeth gently with a soft toothbrush and see a dentist regularly for checkups. Public pools and hot tubs should be avoided, especially if the patient has any cuts or scrapes on the skin, as these can be sources of infection. No one should smoke around patients with aplastic anaemia, as smoke irritates the lungs and increases infection risk.^[14][15]

Nutrition and food safety

Eating a healthy diet is important for maintaining strength and supporting the immune system. However, patients with aplastic anaemia need to be extra careful about food safety because their bodies cannot fight off foodborne illnesses as effectively as healthy individuals. Raw or undercooked foods, including meat, eggs, and seafood, should be avoided. All food should be cooked thoroughly. Fresh fruits and vegetables should be washed well and peeled before eating.^[14][15]

Patients should avoid unpasteurized milk, juices, and aged cheeses, as these products can contain bacteria. Salad bars and restaurant buffets are risky because foods may not be kept at safe temperatures and can be contaminated by many people handling the serving utensils. If patients or their families have questions about what foods are safe, they should ask their healthcare provider for a referral to a registered dietitian who can provide personalized guidance.^[14][15]

Physical activity and rest

Regular exercise and physical activity are beneficial for overall health, but patients with aplastic anaemia need to balance activity with rest. When blood cell counts are low, patients may feel tired or short of breath with exertion. It’s important to listen to the body and rest when needed. If a patient becomes extremely short of breath during activity, they should stop and inform their doctor.^[14][15]

Because low platelet counts increase the risk of bleeding, contact sports and activities with a high risk of injury are usually discouraged. Patients should avoid situations where they could be hit or fall. For children with aplastic anaemia, parents should work with teachers and coaches to ensure that the child can participate safely in school and recreational activities with peers.^[14][15]

Monitoring and follow-up care

Regular medical follow-up is essential for patients with aplastic anaemia. Even when treatment is going well, doctors need to monitor blood counts frequently to ensure that the bone marrow is producing enough cells. Patients may need blood tests as often as weekly during intensive treatment phases, gradually decreasing to monthly or less frequent testing as the condition stabilizes.^[11]

Long-term monitoring is also important because some patients may experience complications years after initial treatment. There is a small risk that aplastic anaemia can evolve into other bone marrow disorders, such as myelodysplastic syndrome or leukemia. Regular checkups allow doctors to detect any concerning changes early and intervene promptly.^[2][9]